What does GOODLIFE PHARMA do?

GOODLIFE PHARMA is a wholesaler in Chastre. Public Limited, started on 11 April 2012, 1 establishment.

What is the address of GOODLIFE PHARMA?

The registered office of GOODLIFE PHARMA is located at Rue François-Massart 27, 1450 Chastre.

Is GOODLIFE PHARMA still active?

Yes. According to the CBE (29 October 2026) GOODLIFE PHARMA is active, legal situation “Normale toestand”, started on 11 April 2012.

Is GOODLIFE PHARMA registered on Peppol?

Yes, GOODLIFE PHARMA is registered on the Peppol network with ID 0208:0845590372.

What is the enterprise number of GOODLIFE PHARMA?

The enterprise number of GOODLIFE PHARMA is BE0845590372.

When was GOODLIFE PHARMA founded?

GOODLIFE PHARMA was founded on 11 April 2012.

Who are the directors of GOODLIFE PHARMA?

According to the 2025 annual accounts, the directors of GOODLIFE PHARMA are: Schewebach BV, Belvita Healtcare, Sterq Management BV, Nathalie Schewebach.

Is GOODLIFE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 April 2012; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did GOODLIFE PHARMA make in 2025?

GOODLIFE PHARMA posted a profit after taxes of € 119,670 in financial year 2025.

What is the revenue of GOODLIFE PHARMA?

As a small company, GOODLIFE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,153,894.

How much does an employee at GOODLIFE PHARMA earn?

The average wage cost per full-time employee at GOODLIFE PHARMA was € 141,400 in 2025: staff costs of € 466,563 for 3.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does GOODLIFE PHARMA have?

According to the 2025 annual accounts, GOODLIFE PHARMA has 3.3 full-time equivalents (FTE).

GOODLIFE PHARMA (Public Limited) - Chastre - BE0845590372

Dossier GOODLIFE PHARMA, printed on 29 October 2026 from databakkes.be/en/0845590372/goodlife-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

GOODLIFE PHARMA from Chastre, company number BE0845590372, closed financial year 2025 with a result of € 119,670 after tax. For that financial year GOODLIFE PHARMA recorded a gross margin of € 1.2 million and equity of € 769,473. Compared with financial year 2024, the result moved from € 259,803 to € 119,670. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Growing

€ 769,473

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 119,670

▼ 54% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 214,829

▲ € 176,410 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 506,973.

People and assets in 2025

Full-time equivalents

3.3

▲ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 466,563

▼ 5% vs 2024

€ 141,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 7,571

▼ 42% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 2.9 million

▲ 54% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 312,749

▼ 85% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 99,965

▲ 56% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 478,986 Gross margin 2022: € 478,986 First fiscal year in the series	€ 584,792 Gross margin 2023: € 584,792 ▲ 22% vs 2022 (€ 478,986) Favourable step	€ 917,755 Gross margin 2024: € 917,755 ▲ 57% vs 2023 (€ 584,792) Favourable step	€ 1,153,894 Gross margin 2025: € 1,153,894 ▲ 26% vs 2024 (€ 917,755) Favourable step	▲ 26%
Profit after taxes	€ 220,928 Profit after taxes 2022: € 220,928 First fiscal year in the series	€ 268,956 Profit after taxes 2023: € 268,956 ▲ 22% vs 2022 (€ 220,928) Favourable step	€ 259,803 Profit after taxes 2024: € 259,803 ▼ 3% vs 2023 (€ 268,956) Unfavourable step	€ 119,670 Profit after taxes 2025: € 119,670 ▼ 54% vs 2024 (€ 259,803) Unfavourable step	▼ 54%
Equity	€ 121,043 Equity 2022: € 121,043 First fiscal year in the series	€ 389,999 Equity 2023: € 389,999 ▲ 222% vs 2022 (€ 121,043) Favourable step	€ 649,802 Equity 2024: € 649,802 ▲ 67% vs 2023 (€ 389,999) Favourable step	€ 769,473 Equity 2025: € 769,473 ▲ 18% vs 2024 (€ 649,802) Favourable step	▲ 18%
Total debts	€ 1,955,350 Total debts 2022: € 1,955,350 First fiscal year in the series	€ 4,187,557 Total debts 2023: € 4,187,557 ▲ 114% vs 2022 (€ 1,955,350) Unfavourable step	€ 4,471,259 Total debts 2024: € 4,471,259 ▲ 7% vs 2023 (€ 4,187,557) Unfavourable step	€ 3,534,949 Total debts 2025: € 3,534,949 ▼ 21% vs 2024 (€ 4,471,259) Favourable step	▼ 21%
Cash	€ 39,596 Cash 2022: € 39,596 First fiscal year in the series	€ 206,265 Cash 2023: € 206,265 ▲ € 166,669 vs 2022 (€ 39,596) Favourable step	€ 38,419 Cash 2024: € 38,419 ▼ 81% vs 2023 (€ 206,265) Unfavourable step	€ 214,829 Cash 2025: € 214,829 ▲ € 176,410 vs 2024 (€ 38,419) Favourable step	▲ € 176,410
Retained profit	€ -141,457 Retained profit 2022: € -141,457 First fiscal year in the series	€ 127,499 Retained profit 2023: € 127,499 ▲ € 268,956 vs 2022 (€ -141,457) Favourable step	€ 387,302 Retained profit 2024: € 387,302 ▲ 204% vs 2023 (€ 127,499) Favourable step	€ 506,973 Retained profit 2025: € 506,973 ▲ 31% vs 2024 (€ 387,302) Favourable step	▲ 31%
Bank debt	€ 990,000 Bank debt 2022: € 990,000 First fiscal year in the series	€ 1,890,000 Bank debt 2023: € 1,890,000 ▲ 91% vs 2022 (€ 990,000) Unfavourable step	€ 1,890,000 Bank debt 2024: € 1,890,000 Unchanged (€ 1,890,000) Unchanged	€ 2,915,000 Bank debt 2025: € 2,915,000 ▲ 54% vs 2024 (€ 1,890,000) Unfavourable step	▲ 54%
Balance sheet total	€ 2,076,393 Balance sheet total 2022: € 2,076,393 First fiscal year in the series	€ 4,577,556 Balance sheet total 2023: € 4,577,556 ▲ 120% vs 2022 (€ 2,076,393) Unchanged	€ 5,121,062 Balance sheet total 2024: € 5,121,062 ▲ 12% vs 2023 (€ 4,577,556) Unchanged	€ 4,304,421 Balance sheet total 2025: € 4,304,421 ▼ 16% vs 2024 (€ 5,121,062) Unchanged	▼ 16%
Employees (FTE)	1.8 Employees (FTE) 2022: 1.8 First fiscal year in the series	1.8 Employees (FTE) 2023: 1.8 Unchanged (1.8) Unchanged	2.7 Employees (FTE) 2024: 2.7 ▲ 0.9 vs 2023 (1.8) Unchanged	3.3 Employees (FTE) 2025: 3.3 ▲ 0.6 vs 2024 (2.7) Unchanged	▲ 0.6

Key figures of GOODLIFE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to GOODLIFE PHARMA?

What happened at GOODLIFE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: profit of € 119,670 (▼ 54% vs 2024). filed late Source: NBB ↗
2026 Schewebach BV became a director. NBB
2026 Belvita Healtcare became a director. NBB
2026 Nathalie Schewebach stepped down as director. NBB
2023 Nathalie Schewebach became a director. NBB
Apr 11, 2012 New establishment in Chastre. KBO
Apr 11, 2012 Start of the company according to the CBE. KBO

In short

From € 220,928 profit in 2022 to € 119,670 profit in 2025.

Paid € 145,067 in corporate taxes since 2022.

Best year ever: 2023, with € 268,956 profit.

On average € 349,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Schewebach BV Belvita Healtcare Sterq Management BV

GOODLIFE PHARMA

Behind GOODLIFE PHARMA are Schewebach BV, Belvita Healtcare and Sterq Management BV.

Directors

According to the 2025 annual accounts

Schewebach BV

Director · represented by Nathalie Schewebach

since 2026

Belvita Healtcare

Director · represented by Koen Perenboom

since 2026

Sterq Management BV

Managing director · represented by Koen Perenboom

Nathalie Schewebach

Director

since 2023 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Rue François-Massart 27

1450 Chastre

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

SCHEWEBACH same network

€ 38,349 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0845.590.372

VAT number

BE 0845.590.372

Registered office

Rue François-Massart 27, 1450 Chastre

Names & denominations

GOODLIFE PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

11 April 2012

Peppol

Active · Active since 21 Oct 2026

Contact

[email protected] 0497583306

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Detailhandel in farmaceutische producten

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

GOODLIFE PHARMA

Financials

What happened to GOODLIFE PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions